Navigation Links
Contrast agent guidelines help prevent debilitating disorder
Date:5/16/2011

OAK BROOK, Ill. A simple blood test may help prevent a serious complication associated with a contrast agent commonly used in MRI exams, according to a study published in the July issue of Radiology.

Within the past five years, use of gadolinium-based contrast agents (GBCA) has been linked to the development of nephrogenic systemic fibrosis (NSF), a rare disorder mainly affecting patients with severe kidney disease. But since 2008, restrictive GBCA administration guidelines implemented by Massachusetts General Hospital have proven effective in preventing NSF.

"It is important for the public to know that gadolinium products are safe for most patients and the risk of NSF should not deter them from GBCA-enhanced exams, such as MRIs," said the study's lead author Hani H. Abujudeh, M.D., M.B.A., associate professor of radiology at Harvard Medical School in Boston.

NSF is characterized by widespread tissue fibrosis. Patients with NSF experience an increase of collagen in the tissues, causing thickening and hardening of the skin of the extremities, and often resulting in immobility and tightening or deformity of the joints. NSF can develop rapidly and may result in patients becoming wheelchair-bound within just a few weeks. In some cases, there is involvement of other tissues, including the lungs, heart, diaphragm, esophagus and skeletal muscle.

Massachusetts General Hospital began implementing restrictive GBCA guidelines in May 2007 in order to protect patients from possibly developing NSF. The guidelines require that a blood test be done on patients over age 60 or at risk for kidney disease. The blood test measures how well the kidneys are doing. That number is then converted via a formula to estimate the glomerular filtration rate (eGFR), which measures the rate of fluid flow through the kidneys. The guidelines stipulate a maximum GBCA dose of 20mL for patients with a low eGFR (below 60 mL/ min/m2). GBCA should not be administered at all to patients currently undergoing dialysis treatment or with a very low eGFR (below 30 mL/min/ m2).

For the study, Dr. Abujudeh and colleagues reviewed the hospital's medical records during the pre-guideline and transition period (January 2002 through December 2007) and the post-adoption period (January 2008 to March 2010). Prior to adoption of the guidelines and during the transition period, 113,120 contrast-enhanced MRI exams were performed, and 34 cases of NSF were subsequently identified. During the post-guideline period, 52,954 contrast-enhanced MRIs were performed with no new cases of NSF identified.

"The findings prove that these guidelines are effective," Dr. Abujudeh said, "and that strategies can be put into practice to ensure patient safety."


'/>"/>

Contact: Linda Brooks
lbrooks@rsna.org
630-590-7762
Radiological Society of North America
Source:Eurekalert

Related medicine news :

1. Contrast-enhanced MRI could play a key role in differentiating between common types of arthritis
2. Improved protocols for contrast agents eliminates new cases of nephrogenic systemic fibrosis
3. Professional Insurance Agents to Hold 2010 Federal Legislative Summit March 17-18
4. Long Term Care Insurance Leader Seeks 320 New Agents in 2010, Following Strong 2009 Growth
5. Professional Insurance Agents Name Rep. Charlie Melancon 2010 Legislator of the Year
6. Overcoming tumor resistance to anti-cancer agent TRAIL
7. Scott & White Healthcare researchers studying investigational agent that targets breast cancer
8. Targeted agent blocked growth of deadly brain cancer in preclinical studies
9. New agent chokes off energy supply, kills cancer cells
10. Health Insurance Agents Work with Zane Benefits to Offer New Solutions amid Health Care Reform
11. Mayo-led research team develop agents that keep insulin working longer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis pubis may be commonplace ... injury, it occurs when the muscles around the pelvis become inflamed. Over time, ... lower torso, as well as accompanying tenderness and weakness. Without proper intervention, it ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... epigenetic research products enables researchers to pursue the recent RNA methylation “gold rush” ... . In light of the newfound characteristics of N6-methyladenosine, or m6A , ...
(Date:3/27/2017)... ... March 27, 2017 , ... Janet Schloz is still in shock after receiving a $2,500 ... had in a long time,” she said. , She thinks the coming week is going ... never thought I would have to help my students.” , The award will allow the ...
(Date:3/27/2017)... ... March 27, 2017 , ... Sodium ... methods are complicated and require expert user knowledge. In a live webinar on ... to the simplified, yet highly accurate, determination of sodium. , It has long ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... facility from 8:00am-10:00am on Monday, April 3rd to commemorate the two-year anniversary of ... opportunity for area-residents to celebrate two great years while also familiarizing themselves with ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017  Cryoport, Inc. (NASDAQ: CYRX, ... intends to offer shares of common stock in an ... on file with the Securities and Exchange Commission (the ... conditions, and there can be no assurance as to ... as to the actual size or terms of the ...
(Date:3/27/2017)... 2017 To mark the end of Save Your ... leader in digital imaging solutions, will showcase Canon eye care ... New York,s Jacob Javits Center from ... sponsored by the American Optometric Association, is observed annually in ... comprehensive eye exams. In recognition of this observance, Canon ...
(Date:3/27/2017)... March 27, 2017  Sophiris Bio Inc. (NASDAQ: ... a clinical late-stage biopharmaceutical company developing topsalysin (PRX302) ... today reported fourth quarter and full year 2016 ... Key Corporate Highlights: Advanced ... Cancer. During 2016, the Company reported successful results ...
Breaking Medicine Technology: